Ameriprise Financial Inc. Raises Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Ameriprise Financial Inc. boosted its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 187.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,784 shares of the company's stock after purchasing an additional 63,067 shares during the period. Ameriprise Financial Inc. owned about 0.13% of Trevi Therapeutics worth $399,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC increased its holdings in Trevi Therapeutics by 14.5% in the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company's stock worth $110,000 after acquiring an additional 3,387 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Trevi Therapeutics by 2.1% during the fourth quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company's stock worth $578,000 after purchasing an additional 2,935 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Trevi Therapeutics by 14.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company's stock worth $713,000 after purchasing an additional 22,145 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Trevi Therapeutics in the fourth quarter valued at approximately $49,000. Finally, Rosalind Advisors Inc. raised its position in shares of Trevi Therapeutics by 41.7% in the fourth quarter. Rosalind Advisors Inc. now owns 1,062,500 shares of the company's stock valued at $4,378,000 after purchasing an additional 312,500 shares during the period. Institutional investors own 95.76% of the company's stock.

Insiders Place Their Bets

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares of the company's stock, valued at approximately $519,075. The trade was a 51.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jennifer L. Good sold 5,263 shares of the company's stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the completion of the sale, the chief executive officer now owns 213,313 shares in the company, valued at approximately $1,403,599.54. This trade represents a 2.41% decrease in their position. The disclosure for this sale can be found here. Insiders own 18.30% of the company's stock.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock traded up $0.32 during mid-day trading on Friday, hitting $7.06. 2,488,341 shares of the company traded hands, compared to its average volume of 1,317,209. Trevi Therapeutics, Inc. has a one year low of $2.30 and a one year high of $7.48. The stock has a market cap of $705.24 million, a price-to-earnings ratio of -16.05 and a beta of 0.59. The stock has a fifty day moving average price of $6.24 and a 200-day moving average price of $4.96.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.04. Sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Wall Street Analyst Weigh In

TRVI has been the subject of several analyst reports. HC Wainwright assumed coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price for the company. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price target for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Oppenheimer restated an "outperform" rating on shares of Trevi Therapeutics in a research report on Monday. D. Boral Capital reaffirmed a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Monday. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of Trevi Therapeutics in a research note on Tuesday, May 20th. Seven research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Trevi Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $18.63.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.